Investigational Drug Details
| Drug ID: | D269 |
| Drug Name: | PF-06835919 |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | Ketohexokinase inhibitor |
| Therapeutic Category: | Enhance lipid metabolism |
| Clinical Trial Progress: | Phase 2 completed (NCT04193436) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0065 | NCT03256526 | Phase 2 | Completed | Has Results | September 27, 2017 | April 4, 2019 | Details |
| L0119 | NCT03969719 | Phase 2 | Completed | No Results Available | July 18, 2019 | August 5, 2021 | Details |
| L0837 | NCT02974374 | Phase 1 | Not recruiting | No Results Available | 11/10/2016 | 8 January 2018 | Details |
| L0990 | NCT04193436 | Phase 1 | Completed | No Results Available | January 21, 2020 | August 12, 2021 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A04317 | 33667726 | Mol Metab | Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. | Details |
| A06369 | 32910646 | J Med Chem | Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose. | Details |
| A07203 | 32583961 | Clin Transl Sci | Evolving Role for Pharmacotherapy in NAFLD/NASH. | Details |
| A49355 | 35779864 | Drug Metab Dispos | Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, A First-in-class Ketohexokinase Inhibitor for Metabolic Disorders and Non-alcoholic Fatty Liver Disease. | Details |
| A49931 | 35590219 | Med (N Y) | Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial. | Details |